

Genetics in Neurodegenerative Diseases



Coordinator

Clarimon Echavarría, Jordi IR
jclarimon@santpau.cat

Members

Cervera Carles, Laura IR
Dols Icardo, Oriol IR
Muñoz Llahuna, Laia CIBERNED

Main Lines of Research

- ▶ Use of state-of-the-art genomic strategies to study the genetic architecture of complex diseases caused by neurodegenerative processes, including Alzheimer disease and other dementias, Parkinson disease, and amyotrophic lateral sclerosis (ALS), among others.
- ▶ Cloning and evaluation of novel genes associated with neurodegenerative disorders through genomic analyses on families with Mendelian pattern of inheritance.
- ▶ Study of the relationship between biomarkers and endophenotypes at the individual genetic background.
- ▶ Evaluation of the effect of novel genes related to neurodegenerative disorders in the Spanish population through multi-centre collaborative studies.

Challenges

- ▶ Assemble a research team of excellence in the international field of genetics of neurodegenerative disorders.
- ▶ Increase our capacity of funding through EU support.
- ▶ Develop a comprehensive genomic database from well-characterized Spanish patients of European origin suffering from neurodegenerative disorders.

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Neurobiology of Dementia.
- ▶ Parkinson Disease and Movement Disorders.
- ▶ Neuromuscular Diseases.

External Collaborations

National and international consortiums

- ▶ European Early-Onset Dementia Consortium (EU-EOD)
- ▶ European Alzheimer Disease Initiative (EADI)
- ▶ International Genomics of Alzheimer Project (IGAP)
- ▶ International Parkinson's Disease Genetic Consortium (IPDGC)
- ▶ International Frontotemporal Dementia Genomics Consortium (IFGC)
- ▶ Dementia Genetics Spanish Consortium (DEGESCO)

- ▶ CIBER-Neurodegenerative Diseases (CIBER-NED)

Collaborations with international centres

- ▶ Dr. John Hardy, University College of London, UK.
- ▶ Dr. Andrew Singleton, National Institutes of Health, USA.
- ▶ Dr. Jean-Charles Lambert, Directeur de recherche Inserm chez INSERM. Lille, France.
- ▶ Dr. Alfredo Ramírez, University of Bonn, Germany.
- ▶ Dr. Ekaterina Rogaeva, University of Toronto, Canada.
- ▶ Dr. Mikko Hiltunen, Kuopio University, Finland.
- ▶ Dr. Martin Ingelsson, Uppsala University, Sweden.
- ▶ Dr. Liana Fidani, Aristotle University of Thessaloniki, Greece.
- ▶ Dr. Christine Van Broekhoven, University of Antwerp, Belgium.

Grants Awarded in 2017

- ▶ Oriol Dols Icardo. Estudi del paper de les variants genètiques rares en l'arquitectura genètica de la malaltia d'Alzheimer. SLT002/16/00040. Departament de Salut. Duration: 2017-2019. 88.376,57 €.
- ▶ Jordi Clarimon Echavarría, Estudio del splicing alternativo en ARN de muestras con diagnóstico neuropatológico de ELA asociada a TDP-43. FUNDELA 2017. Fundació Espanyola per al Foment de la Investigació de l'Esclerosi Lateral Amiotròfica. Duration: 2017-2018. 26.087,00 €.

Note: Total amount granted to PI. It does not include indirect costs.

Active Grants

- ▶ Jordi Clarimon Echavarria. Estudio del perfil de expresión de microRNA exosomal en biofluidos para la identificación de biomarcadores de uso diagnóstico en la demencia frontotemporal. PI15/00026. Instituto de Salud Carlos III. Duration: 2016-2018. 101,500.00 €.
- ▶ Jordi Clarimon Echavarria. Unitat genètica malalties neurodegeneratives. IR16-P7. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 7,000.00 €.
- ▶ Jordi Clarimon Echavarria. A comprehensive genomic analysis of patients with motor neuron disease and frontotemporal dementia to disentangle the missing genetic architecture of amyotrophic lateral sclerosis TODOS SOMOS RAROS 2014. Federación Española de Enfermedades Raras / Fundación Isabel Gemio / Federación Española de Enfermedades Neuromusculares. Duration: 2015-2017. 90,748.00 €.
- ▶ Jordi Clarimon Echavarria. Grup de Recerca en Demències. 2014 SGR 235. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2014-2017. 18,000.00 €.
- ▶ Jordi Clarimon Echavarria. Contratos Miguel Servet 2013 (II). MSII13/00005. Instituto de Salud Carlos III. Duration: 2014-2017. 101,250.00 €.
- ▶ Jordi Clarimon Echavarria. Grup de Recerca en Demències: Sant Pau. 2017 SGR 547. Agència de Gestió d'Ajuts Universitaris i de Recerca. Duration: 2017-2019. 35,200.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

*TIF: 122.507 **MIF: 7.6566

Scientific Production

- Alcolea D., Vilaplana E., Suarez-Calvet M., Illan-Gala I., Blesa R., Clarimon J., Llado A., Sanchez-Valle R., Molinuevo J.L., Garcia-Ribas G., Compta Y., Marti M.J., Pinol-Ripoll G., Amer-Ferrer G., Noguera A., Garcia-Martin A., Fortea J., Lleo A., CSF sAPP β , YKL-40, and neurofilament light in frontotemporal lobar degeneration (2017) *NEUROLOGY*, 89 (2), 178-188. **IF: 7.180**
- Carmona-Iragui M., Balasa M., Benejam B., Alcolea D., Fernandez S., Videla L., Sala I., Sanchez-Saudinos M.B., Morenas-Rodriguez E., Ribosa-Nogue R., Illan-Gala I., Gonzalez-Ortiz S., Clarimon J., Schmitt F., Powell D.K., Bosch B., Llado A., Rafii M.S., Head E., Molinuevo J.L., Blesa R., Videla S., Lleo A., Sanchez-Valle R., Fortea J., Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease (2017) *ALZHEIMERS DEMENT*, 13 (11), 1251-1260. **IF: 11.980**
- Cervera-Carles L., Alcolea D., Estanga A., Ecay-Torres M., Izagirre A., Clerigue M., Garcia-Sebastian M., Villanua J., Escalas C., Blesa R., Martinez-Lage P., Lleo A., Fortea J., Clarimon J., Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum (2017) *NEUROBIOL AGING*, 53, 192.e1-192.e4. **IF: 4.225**
- Colom-Cadena M., Grau-Rivera O., Planellas L., Cerquera C., Morenas E., Helgueta S., Munoz L., Kulisevsky J., Marti M.J., Tolosa E., Clarimon J., Lleo A., Gelpi E., Regional overlap of pathologies in lewy body disorders (2017) *J NEUROPATH EXP NEUR*, 76 (3), 216-224. **IF: 3.271**
- Compta Y., Ramos-Campoy O., Grau-Rivera O., Colom-Cadena M., Clarimón J., Martí MJ, Gelpi E., Conjoint FTLD-FUS of the neuronal intermediate filament inclusion disease type, progressive supranuclear palsy, and mild Alzheimer's pathology presenting as parkinsonism with early falls and late hallucinations, psychosis and dementia (2017) *NEUROPATHOL APPL NEUROBIOL*, 43 (4), 352-357. **IF: 6.059**
- Cortes-Vicente E., Pradas J., Marin-Iahoz J., De Luna N., Clarimon J., Turon-Sans J., Gelpi E., Diaz-Manera J., Illa I., Rojas-Garcia R., Early diagnosis of amyotrophic lateral sclerosis mimic syndromes: pros and cons of current clinical diagnostic criteria (2017) *AMYOTROPH LAT SCL FR*, 18 (5-6), 333-340. **IF: 2.467**
- De Roeck A., van Den Bossche T., van der Zee J., Verheijen J., de Coster W., van Dongen J., Dillen L., Baradaran-Heravi Y., Heeman B., Sanchez-Valle R., et al., Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease (2017) *ACTA NEUROPATHOL*, 134 (3), 475-487. **IF: 15.248**
- Gelpi E, Carrato C, Grau-López L, Becerra JL, Garcia-Armengol R, Massuet A, Cervera-Carles L, Clarimon J, Beyer K, Álvarez R. Incidental neuronal intermediate filament inclusion pathology: unexpected biopsy findings in a 37-year old woman with epilepsy (2017) *NEUROPATHOL APPL NEUROBIOL*, 43 (7), 636-640. **IF: 6.059**
- Kun-Rodrigues C., Ross O.A., Orme T., Shepherd C., Parkkinen L., Darwent L., Hernandez D., Ansorge O., Clark L.N., Honig L.S., et al., Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies (2017) *NEUROBIOL AGING*, 49, 214.e13-214.e15. **IF: 4.225**
- Pegueroles J., Vilaplana E., Montal V., Sampedro F., Alcolea D., Carmona-Iragui M., Clarimon J., Blesa R., Lleo A., Fortea J., Longitudinal brain structural changes in preclinical Alzheimer's disease (2017) *ALZHEIMERS DEMENT*, 13 (5), 499-509. **IF: 11.980**
- Querol-Vilaseca M., Colom-Cadena M., Pegueroles J., San Martin-Paniello C., Clarimon J., Belbin O., Fortea J., Lleo A., YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies (2017) *J NEUROINFLAMM*, 14 (1). **IF: 4.910**
- Sala I., Illan-Gala I., Alcolea D., Sanchez-Saudinos M.B., Salgado S.A., Morenas-Rodriguez E., Subirana A., Videla L., Clarimon J., Carmona-Iragui M., Ribosa-Nogue R., Blesa R., Fortea J., Lleo A., Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease (2017) *J ALZHEIMERS DIS*, 58 (3), 909-918. **IF: 3.071**
- Sims R., Van Der Lee S.J., Naj A.C., Bellenguez C., Badarinarayan N., Jakobsdottir J., Kunkle B.W., Boland A., Raybould R., Bis J.C., et al., Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) *NAT GENET*, 49 (9), 1373-1384. **IF: 26.192**
- Spataro N., Roca-Umbert A., Cervera-Carles L., Valles M., Anglada R., Pagonabarraga J., Pascual-Sedano B., Campolongo A., Kulisevsky J., Casals F., Clarimon J., Bosch E., Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients (2017) *MOVEMENT DISORD*, 32 (1), 165-169. **IF: 7.596**
- Tell-Martí G., Puig-Butille J.A., Potrony M., Plana E., Badenas C., Antonell A., Sanchez-Valle R., Molinuevo J.L., Lleo A., Alcolea D., Fortea J., Fernandez-Santiago R., Clarimon J., Llado A., Puig S., A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk (2017) *J ALZHEIMERS DIS*, 56 (3), 1065-1074. **IF: 3.071**
- Van der Zee J., Gijssels I., Van Mossevelde S., Perrone F., Dillen L., Heeman B., Baumer V., Engelborghs S., De Bleecker J., Baets J., et al., TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis (2017) *HUM MUTAT*, 38 (3), 297-309. **IF: 4.973**